Leblond V, Aktan M, Coll CMF, Dartigeas C, Kisro J, Montillo M, Raposo J, Merot J-L, Robson S, Gresko E, Bosch F, Stilgenbauer S, Foà R. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Haematologica [Internet]. 2018Oct.31 [cited 2026Nov.12];103(11):1889-98. Available from: https://haematologica.org/article/view/8667